Reply to Joe O`Sullivan, Daniel Heinrich, Nicholas D. James, et al.`s Letter to the Editor re: The Case Against the European Medicines Agency`s Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.11.003 (European Urology)
EMA welcomes this opportunity to comment on the letter from O`Sullivan et al. [1] regarding the recommendation of the European Medicines Agency (EMA) on Xofigo (radium-223 dichloride).